| ★ |  The transition from benign to secondary Raynaud’s phenomenon | | 186 | — | |
| 8 |  Hydroxychloroquine in connective tissue diseases: benefits and controversial aspects | | 1.8K | — | 87 |
| 16 |  From basics to updates for cutaneous lupus erythematosus (CLE) | | 1.1K | — | 87 |
| 7 |  ERN ReCONNET: the New 2026 Webinar Series | | 630 | — | 88 |
| 6 |  Quality of life in Relapsing Polychondritis (RP) | | 412 | — | 88 |
| 4 |  Why morning joint stiffness and swelling in rheumatic diseases? | | 398 | — | 88 |
| 18 |  Pregnancy in women with primary Sjögren’s disease | | 380 | — | 87 |
| 19 |  Treatment of systemic sclerosis-associated interstitial lung disease: where do we stand in 2025? | | 285 | — | 86 |
| 17 |  Microvascular Involvement in Antiphospholipid Syndrome (APS) | | 264 | — | 87 |
| 10 |  Exercise as a non-pharmacological treatment adjunct to pharmacotherapy in systemic sclerosis. | | 222 | — | 87 |
| 12 |  Exercise in adult idiopathic inflammatory myopathies (IIMs) | | 188 | — | 87 |
| 5 |  Imaging in Relapsing Polychondritis (RP) | | 171 | — | 88 |
| 13 |  Everything you always wanted to know about Ehlers-Danlos Syndromes (EDS) – Part two | | 151 | — | 87 |
| 20 |  Unconventional therapies in connective tissue diseases | | 110 | — | 86 |
| 2 |  Vaccination in undifferentiated connective tissue disease (UCTD) | | 103 | — | 89 |
| 3 |  Osteoporosis in rare and complex connective tissue diseases | | 96 | — | 89 |
| 11 |  Unmet Needs in Childhood-Onset Sjögren's Disease – Patient and Clinician Perspectives | | 82 | — | 87 |
| 14 |  Pregnancy in undifferentiated connective tissue disease (UCTD) | | 72 | — | 87 |
| 9 |  Multidisciplinary diagnosis and team treatment in Idiopathic Inflammatory Myopathies | | 64 | — | 87 |
| 15 |  “Doctor, can you ask me…?” for connective tissue diseases patients | | 46 | — | 87 |
| 1 |  Genetic Testing in the Era of NGS: Lessons from the Hereditary Connective Tissue Disorders | | 35 | — | 89 |